[go: up one dir, main page]

HK1212995A1 - A method of purifying proteins - Google Patents

A method of purifying proteins Download PDF

Info

Publication number
HK1212995A1
HK1212995A1 HK16100830.6A HK16100830A HK1212995A1 HK 1212995 A1 HK1212995 A1 HK 1212995A1 HK 16100830 A HK16100830 A HK 16100830A HK 1212995 A1 HK1212995 A1 HK 1212995A1
Authority
HK
Hong Kong
Prior art keywords
purifying proteins
purifying
present
proteins
hemopexin
Prior art date
Application number
HK16100830.6A
Other languages
Chinese (zh)
Inventor
Nathan Brinkman
Original Assignee
Csl Behring Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/803,525 external-priority patent/US9534029B2/en
Application filed by Csl Behring Ag filed Critical Csl Behring Ag
Publication of HK1212995A1 publication Critical patent/HK1212995A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1722—Plasma globulins, lactoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4717—Plasma globulins, lactoglobulin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates generally to a method of purifying proteins. More specifically, the present inventions relates to a method of purifying haptoglobin and hemopexin from the same starting material, and uses thereof.
HK16100830.6A 2012-10-03 2013-10-01 A method of purifying proteins HK1212995A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261709342P 2012-10-03 2012-10-03
US13/803,525 2013-03-14
US13/803,525 US9534029B2 (en) 2012-10-03 2013-03-14 Method of purifying proteins
AU2013203930 2013-04-11
AU2013203930A AU2013203930B2 (en) 2012-10-03 2013-04-11 A method of purifying proteins
EP13170202 2013-06-03
PCT/US2013/062916 WO2014055552A1 (en) 2012-10-03 2013-10-01 A method of purifying proteins

Publications (1)

Publication Number Publication Date
HK1212995A1 true HK1212995A1 (en) 2016-06-24

Family

ID=52824845

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16100830.6A HK1212995A1 (en) 2012-10-03 2013-10-01 A method of purifying proteins

Country Status (8)

Country Link
EP (1) EP2904005A1 (en)
JP (2) JP6370792B2 (en)
KR (2) KR102125695B1 (en)
CN (2) CN104968676A (en)
CA (2) CA2886726C (en)
HK (1) HK1212995A1 (en)
SG (1) SG11201501921SA (en)
WO (1) WO2014055552A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3334441B1 (en) * 2015-08-13 2021-06-16 Kamada Ltd. Compositions derived from cohn fraction paste and use thereof
US20190276521A1 (en) * 2016-03-29 2019-09-12 Kyowa Hakko Kirin Co., Ltd. Therapeutic agent for treatment of autoimmune diseases containing antibody binding to haptoglobin in blood and forming polyvalent immune complex as an active component
CN111432880A (en) * 2017-08-08 2020-07-17 瑞士杰特贝林生物制品有限公司 Hemoglobin binding protein formulations
CN111989568B (en) * 2018-04-18 2024-05-28 积水医疗株式会社 Hemoglobin analysis method
US20220211808A1 (en) 2019-05-17 2022-07-07 Universitaet Zuerich Haptoglobin for use in treating an adverse secondary neurological outcome following a haemorrhagic stroke
CA3179750A1 (en) * 2020-04-10 2022-04-07 Plasma Technologies, Llc Compositions and methods for simplified high efficiency isolation of proteins
KR20230142569A (en) 2021-02-01 2023-10-11 체에스엘 베링 아게 Methods for Treating or Preventing Secondary Neurological Adverse Events After Hemorrhagic Stroke
KR102728329B1 (en) * 2021-02-04 2024-11-08 주식회사 녹십자 A Method of purifying hemopexin and haptoglobin
KR20250123923A (en) 2022-12-22 2025-08-18 체에스엘 베링 아게 Method for purifying hemopexin using mixed mode chromatography
CN116179636A (en) * 2023-01-12 2023-05-30 合肥工业大学 Coproduction preparation method of heme and globin
WO2025168750A1 (en) 2024-02-09 2025-08-14 Csl Behring Ag Haptoglobin for use in treating traumatic brain injury (tbi)
WO2025257801A1 (en) 2024-06-13 2025-12-18 CSL Innovation Pty Ltd Heme-binding protein for the treatment of ischemia-reperfusion injury (iri)

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1426039A (en) * 1973-11-15 1976-02-25 Green Cross Corp Haptoglobin in aqueous solution and process for tits preparation
JPS5337406B2 (en) * 1973-11-15 1978-10-09
US4129648A (en) * 1977-11-21 1978-12-12 Collier Harry O J Method for reducing endogenous prostaglandin synthesis
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US4764369A (en) 1983-07-14 1988-08-16 New York Blood Center Inc. Undenatured virus-free biologically active protein derivatives
JPS6317899A (en) * 1986-07-09 1988-01-25 Green Cross Corp:The Purification of haptoglobin
JPH01305036A (en) * 1988-05-31 1989-12-08 Green Cross Corp:The Heat-treatment of plasma protein component and drug preparation containing plasma protein component
US5169936A (en) * 1989-04-14 1992-12-08 Biogen, Inc. Protein purification on immobilized metal affinity resins effected by elution using a weak ligand
US5138034A (en) * 1989-07-12 1992-08-11 The Green Cross Corporation Method of fractionating plasma proteins
FR2672604B1 (en) * 1991-02-07 1995-05-05 Pasteur Merieux Serums Vacc PROCESS FOR ISOLATING HUMAN ALBUMIN FROM SURNANTANT IV, PARTICULARLY IV-4, OR FRACTION V OF COHN OR OF A SURNANTANT OR THE LIKE FRACTION.
SE9301582D0 (en) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab PURIFICATION OF PLASMA PROTEINS
DE19830914C1 (en) * 1998-07-10 1999-06-24 Centeon Pharma Gmbh Preparation of a protein solution, especially albumin solution for use as blood volume substitute in emergency situations, and solution containing blood coagulation factors
US6093804A (en) * 1998-09-24 2000-07-25 American National Red Cross Method for purification of alpha-1 proteinase inhibitor
US6815181B2 (en) * 2001-07-09 2004-11-09 Applera Corporation Nucleic acid molecules encoding human secreted hemopexin-related proteins
DE10211632A1 (en) 2002-03-15 2003-10-09 Aventis Behring Gmbh Process for the separation of viruses from a protein solution by nanofiltration
DE10215315A1 (en) * 2002-04-05 2003-11-20 Aventis Behring Gmbh Intellect Human transferrin for the treatment of anemia of chronic disease (ACD) and functional iron deficiency
WO2003086272A2 (en) * 2002-04-16 2003-10-23 Kamada Ltd. Ultrapure transferrin for pharmaceutical compositions
DE10261126A1 (en) 2002-08-13 2004-03-04 Aventis Behring Gmbh Storage-stable, liquid fibrinogen formulation
JP2004224793A (en) * 2003-01-17 2004-08-12 Research Corp Technologies Inc How to treat endometriosis
JP2004256463A (en) * 2003-02-26 2004-09-16 Univ Waseda Polymorphonuclear leukocyte cell adhesion inhibitor and method for suppressing cell adhesion
GB0423196D0 (en) * 2004-10-19 2004-11-24 Nat Blood Authority Method
US7291338B2 (en) * 2005-03-09 2007-11-06 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
JP2009537812A (en) * 2006-05-15 2009-10-29 デジラブ インコーポレーテッド Biomarker for type 2 diabetes preform and method for detecting the presence or absence of type 2 diabetes preform
PL2183268T3 (en) * 2007-08-17 2013-03-29 Csl Behring Gmbh Methods for purification of alpha-1-antitrypsin and apolipoprotein a-i
EP2027875A1 (en) * 2007-08-23 2009-02-25 Octapharma AG A Process for Isolation and Purification of a Target Protein free of Prion Protein (PrPSC)
KR101426039B1 (en) * 2008-09-11 2014-08-01 삼성테크윈 주식회사 Feature point detection apparatus and method for face / object recognition
FR2942233B1 (en) * 2009-02-19 2015-03-13 Lfb Biotechnologies MEANS FOR PURIFYING BLOOD PLASMA PROTEIN, AND METHODS FOR ITS IMPLEMENTATION
EP2236617A1 (en) * 2009-03-31 2010-10-06 Leukocare Ag Methods of terminal sterilization of biofunctional compositions
WO2011002070A1 (en) * 2009-07-02 2011-01-06 協和発酵キリン株式会社 Pharmaceutical composition for treating iron overload disorders or diseases on which the reduction in iron concentration is effective, which comprises gdf7/bmp12 protein
ES2426098T3 (en) * 2009-07-16 2013-10-21 Institut National de la Santé et de la Recherche Médicale Pharmaceutical compositions and their use in cancer treatment
ES2360782B1 (en) * 2009-07-28 2012-03-12 Grifols, S.A. Means for culturing mammalian cells comprising supernatant of stages of Cohn fractionation and use thereof.
SG178306A1 (en) * 2009-08-11 2012-03-29 Biocon Ltd Chromatographic processes and purified compounds thereof
WO2011131720A1 (en) * 2010-04-20 2011-10-27 Octapharma Ag New stabilizing agent for pharmaceutical proteins
WO2012050874A2 (en) * 2010-09-28 2012-04-19 Soares Miguel P Targeting heme for the treatment of immune mediated inflammatory diseases

Also Published As

Publication number Publication date
KR102125695B1 (en) 2020-06-24
JP6876655B2 (en) 2021-05-26
CN104968676A (en) 2015-10-07
SG11201501921SA (en) 2015-04-29
CA2886726A1 (en) 2014-04-10
JP2015532301A (en) 2015-11-09
KR102231613B1 (en) 2021-03-25
JP6370792B2 (en) 2018-08-08
KR20150063547A (en) 2015-06-09
CA2886726C (en) 2021-11-23
WO2014055552A1 (en) 2014-04-10
CN112717125A (en) 2021-04-30
CA3129057A1 (en) 2014-04-10
CA3129057C (en) 2023-03-07
KR20200075027A (en) 2020-06-25
EP2904005A1 (en) 2015-08-12
JP2018172426A (en) 2018-11-08

Similar Documents

Publication Publication Date Title
HK1212995A1 (en) A method of purifying proteins
WO2013138793A3 (en) Affinity reagants for protein purification
EP3207989A4 (en) Exhaust gas purification catalyst
EP3207990A4 (en) Exhaust gas purification catalyst
EP3207987A4 (en) Exhaust gas purification catalyst
HK1206636A1 (en) Modified polynucleotides for the production of oncology-related proteins and peptides
WO2012131555A3 (en) Hetero-dimeric immunoglobulins
EP2742992A4 (en) Separation membrane, separation membrane element, and production method for separation membrane
HRP20180424T1 (en) SCALABILE LENTIVIRUS VECTOR PRODUCTION SYSTEM COMPATIBLE WITH INDUSTRIAL PHARMACEUTICAL APPLICATIONS
WO2013006544A8 (en) Methods for making multimeric polypeptides
MX2015006324A (en) Methods for the manufacture of proteolytically processed polypeptides.
EP2992021A4 (en) Novel cloning, expression & purification method for the preparation of ranibizumab
EP4375371A3 (en) Methods for the manufacture of proteolytically processed polypeptides
EP3254759A4 (en) Exhaust gas purification catalyst
EP3081777A4 (en) Exhaust gas purification material
EP3067367A4 (en) Method for purifying recombinant protein
EP3231511A4 (en) Exhaust gas purifying catalyst
EP3275545A4 (en) Exhaust gas purification catalyst
EP3275542A4 (en) Exhaust gas purification catalyst
EP3192584A4 (en) Exhaust gas purification catalyst
EP3088411A4 (en) Method for purifying antibody having low isoelectric point
EP3275546A4 (en) Exhaust gas purification catalyst
IN2014DN09798A (en)
WO2013011155A3 (en) Method for preparation of medetomidine
WO2012172119A3 (en) Method for the preparation of medetomidine